The complement system in pediatric acute kidney injury

Pediatr Nephrol. 2023 May;38(5):1411-1425. doi: 10.1007/s00467-022-05755-3. Epub 2022 Oct 6.

Abstract

The complement cascade is an important part of the innate immune system. In addition to helping the body to eliminate pathogens, however, complement activation also contributes to the pathogenesis of a wide range of kidney diseases. Recent work has revealed that uncontrolled complement activation is the key driver of several rare kidney diseases in children, including atypical hemolytic uremic syndrome and C3 glomerulopathy. In addition, a growing body of literature has implicated complement in the pathogenesis of more common kidney diseases, including acute kidney injury (AKI). Complement-targeted therapeutics are in use for a variety of diseases, and an increasing number of therapeutic agents are under development. With the implication of complement in the pathogenesis of AKI, complement-targeted therapeutics could be trialed to prevent or treat this condition. In this review, we discuss the evidence that the complement system is activated in pediatric patients with AKI, and we review the role of complement proteins as biomarkers and therapeutic targets in patients with AKI.

Keywords: Acute kidney injury; Complement; Complement inhibitors.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Atypical Hemolytic Uremic Syndrome / therapy
  • Child
  • Complement Activation
  • Complement System Proteins*
  • Humans
  • Kidney Diseases* / therapy
  • Kidney* / pathology

Substances

  • Complement System Proteins